Adamas Pharmaceuticals, Inc. (ADMS) Position Decreased by Wells Fargo & Company MN

Wells Fargo & Company MN trimmed its stake in Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) by 16.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,713 shares of the specialty pharmaceutical company’s stock after selling 2,453 shares during the period. Wells Fargo & Company MN owned 0.06% of Adamas Pharmaceuticals worth $222,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of ADMS. American International Group Inc. raised its stake in shares of Adamas Pharmaceuticals by 7.1% in the 1st quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock valued at $180,000 after acquiring an additional 682 shares in the last quarter. Alps Advisors Inc. raised its stake in shares of Adamas Pharmaceuticals by 6.7% in the 2nd quarter. Alps Advisors Inc. now owns 20,182 shares of the specialty pharmaceutical company’s stock valued at $353,000 after acquiring an additional 1,272 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Adamas Pharmaceuticals by 212.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 60,897 shares of the specialty pharmaceutical company’s stock valued at $1,066,000 after acquiring an additional 41,436 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Adamas Pharmaceuticals by 2.4% in the 1st quarter. Bank of New York Mellon Corp now owns 65,830 shares of the specialty pharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 1,563 shares in the last quarter. Finally, State of Wisconsin Investment Board raised its stake in shares of Adamas Pharmaceuticals by 11.0% in the 2nd quarter. State of Wisconsin Investment Board now owns 111,000 shares of the specialty pharmaceutical company’s stock valued at $1,941,000 after acquiring an additional 11,000 shares in the last quarter. 76.24% of the stock is currently owned by institutional investors and hedge funds.

Adamas Pharmaceuticals, Inc. (ADMS) opened at $29.96 on Tuesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 8.35 and a quick ratio of 8.32. Adamas Pharmaceuticals, Inc. has a 1 year low of $13.50 and a 1 year high of $30.49.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.01) by ($0.03). Adamas Pharmaceuticals’s quarterly revenue was down 99.3% on a year-over-year basis. During the same period in the prior year, the company earned ($0.66) earnings per share. equities analysts anticipate that Adamas Pharmaceuticals, Inc. will post -3.87 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Adamas Pharmaceuticals, Inc. (ADMS) Position Decreased by Wells Fargo & Company MN” was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.com-unik.info/2017/11/21/adamas-pharmaceuticals-inc-adms-position-decreased-by-wells-fargo-company-mn.html.

A number of research analysts recently weighed in on ADMS shares. Noble Financial reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Wednesday, August 9th. Cowen and Company set a $45.00 price objective on Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. Mizuho reissued a “buy” rating and issued a $48.00 price objective (up from $26.00) on shares of Adamas Pharmaceuticals in a research note on Wednesday, September 13th. Needham & Company LLC reissued a “buy” rating and issued a $38.00 price objective on shares of Adamas Pharmaceuticals in a research note on Sunday, September 17th. Finally, ValuEngine raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $42.00.

Adamas Pharmaceuticals Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Institutional Ownership by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

What are top analysts saying about Adamas Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Adamas Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit